The FDA has recently granted approval for 23andMe Holding Co.'s (NASDAQ:ME) cancer treatment, 23ME-01473! It's akin to a VIP ticket for an exciting journey into new drug possibilities. This treatment is focused on triggering the action of natural killer (NK) cells and T cells to combat cancer. The anticipation is building up as Phase 1 clinical trials are set to commence in the first half of 2024. It's a thrilling moment!
FDA just approved 23andMe's cancer treatment '1473!
- '1473 activates NK cells and T cells against cancer.
- Phase 1 trials kick off in early 2024 – big things ahead!
'1473 targets ULBP6 on cancer cells:
- Blocks soluble ULBP6, boosts Fc receptor-mediated killing.
- Aims to turbocharge the immune system against cancer cells.
Exciting Findings:
- Jennifer Low, Head of Therapeutics, sees '1473 delaying tumor resistance – a game-changer!
- Discovered through 23andMe's genetic goldmine – their research platform.
23andMe's Biopharmaceutical Shift:
- Known for ancestry tests, now diving into biopharma.
- Using genetic data to find new therapeutic targets.
Login